The Fort Worth Press - Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

USD -
AED 3.672498
AFN 65.000023
ALL 82.324126
AMD 360.954502
ANG 1.790403
AOA 917.999843
ARS 1546.245702
AUD 1.480845
AWG 1.8
AZN 1.69704
BAM 1.774194
BBD 2.019595
BDT 124.714249
BGN 1.77347
BHD 0.378283
BIF 3011.049223
BMD 1
BND 1.291133
BOB 11.706702
BRL 5.6704
BSD 1.002676
BTN 94.445982
BWP 14.014686
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.427285
CDF 2315.000247
CHF 0.838445
CLF 0.025355
CLP 997.910145
CNY 6.67175
CNH 6.670535
COP 3319.96
CRC 449.312832
CUC 1
CUP 24.064734
CVE 100.026761
CZK 22.146958
DJF 178.554905
DKK 6.781825
DOP 60.996961
DZD 137.215041
EGP 53.666204
ERN 15
ETB 164.576405
EUR 0.90722
FJD 2.27435
FKP 0.756889
GBP 0.756925
GEL 2.589897
GGP 0.756889
GHS 11.756648
GIP 0.756889
GMD 73.999788
GNF 8883.828946
GTQ 7.665407
GYD 209.778157
HKD 7.845525
HNL 26.963428
HRK 6.831965
HTG 131.493006
HUF 331.085501
IDR 18267
ILS 3.21895
IMP 0.756889
INR 94.05615
IQD 1520.102326
IRR 1913737.493849
ISK 123.920313
JEP 0.756889
JMD 158.434973
JOD 0.709006
JPY 159.380496
KES 130.049912
KGS 87.435502
KHR 4119.418691
KMF 446.999884
KPW 900.00035
KRW 1334.339988
KWD 0.31147
KYD 0.835571
KZT 446.941108
LAK 22570.768945
LBP 89792.715562
LKR 333.502667
LRD 170.460782
LSL 16.951345
LTL 2.95274
LVL 0.60489
LYD 6.463464
MAD 9.936772
MDL 18.213733
MGA 4555.721867
MKD 55.830219
MMK 2100.274506
MNT 3605.662913
MOP 8.103614
MRU 40.552456
MUR 47.810103
MVR 15.402503
MWK 1738.739965
MXN 18.58995
MYR 4.092495
MZN 63.843843
NAD 16.951268
NGN 1343.350271
NIO 36.903315
NOK 9.574275
NPR 151.114437
NZD 1.81089
OMR 0.385095
PAB 1.002667
PEN 3.411771
PGK 4.5757
PHP 63.933502
PKR 277.274459
PLN 3.997335
PYG 6223.068898
QAR 3.655265
RON 4.851503
RSD 106.693821
RUB 82.54671
RWF 1483.473867
SAR 3.763142
SBD 8.097697
SCR 13.875029
SDG 601.501052
SEK 10.075065
SGD 1.288355
SHP 0.752984
SLE 23.049758
SLL 20969.503664
SOS 573.051087
SRD 37.490172
STD 20697.981008
STN 22.225347
SVC 8.773903
SYP 13002.000337
SZL 16.945524
THB 33.869465
TJS 9.24984
TMT 3.5
TND 3.022529
TOP 2.40776
TRY 50.392598
TTD 6.806306
TWD 32.987012
TZS 2651.411999
UAH 45.588969
UGX 4141.134208
UYU 40.639897
UZS 12057.766973
VES 912.87925
VND 25747.5
VUV 120.320092
WST 2.810586
XAF 595.097238
XAG 0.021048
XAU 0.000259672138
XCD 2.70255
XCG 1.807123
XDR 0.707052
XOF 595.097238
XPF 108.186074
YER 236.549835
ZAR 16.97378
ZMK 9001.198917
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.086045
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

New product expected to set a new standard for potency and performance in the estimated $20 billon pre-workout market

Desert Stream Inc., a well-established nutritional and supplement manufacturer of caffeine-based products, engaged for sourcing of ingredients, lab studies, regulatory compliance, and quality control.

Single dose pre-workout supplement expected to be available in specialty retailers of nutritional products in 2025

Text size:

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology, announced today plans to launch a single dose pre-workout supplement utilizing Aspire's patent-pending and proprietary sublingual delivery technology in 2025. Pre-workout supplements are multi-ingredient dietary formulas designed to increase energy and provide nutrients that can help improve athletic performance during every workout and over time.

Aspire's sublingual technology is expected to allow for the rapid absorption of pre-workout supplements utilizing a small, convenient sachet of powdered, flavored product. The Company believes this advanced delivery format is a significant innovation in this important product category, with competitors utilizing powders that are mixed with water. Desert Stream is working with Aspire's science team to finish initial manufacturing and testing of this exciting new product which has been created by Aspire and is anticipated initially to be available in at least three flavors.

The clinically dosed pre-workout formula is expected to be conveniently packaged in a single serving sachet for easy on-the-go use.

Market Overview

According to Straits Research, "The global pre-workout supplements market was valued at USD 19.90 billion in 2023 It is estimated to reach USD 29.77 billion by 2032, growing at a CAGR of 4.58% during the forecast period (2024-2032). The demand for pre-workout supplements is driven by consumers' awareness of the need for fitness supplements and the rising demand for nutritional products that enhance performance. Additionally, the increasing number of fitness centers, health clubs, and gymnasiums, coupled with rising non-traditional users, is also anticipated to increase demand for pre-workout supplements."

"We are excited about the opportunity to leverage our delivery technology into the very large and growing pre-workout supplement market," commented Kraig Higginson, Chief Executive Officer of Aspire. "Many caffeine-based pre-workout products are delivered in liquid formulations and typically consumed thirty minutes before a person begins their fitness program. Much of the caffeine is synthesized in the digestive process and liver, potentially delaying the peak performance boost an athlete or fitness enthusiast is seeking. Utilizing our science-backed approach, Aspire has developed a pre-workout product that uses our sublingual delivery method which will allow users to better control the amount of workout enhancement they need and when it will be delivered in their bodies. When used in combination with an overall fitness program, pre-workout product can deliver real results and help fitness enthusiasts achieve their goals."

About Aspire Biopharma, Inc.

Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com.

Safe Harbor Statement

Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Aspire Biopharma Holdings, Inc.

Contact

TraDigital IR
Kevin McGrath
+1-646-418-7002
[email protected]

SOURCE: Aspire Biopharma Holdings, Inc.



View the original press release on ACCESS Newswire

A.Nunez--TFWP